Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Nov 1;178(11):1208-1215.
doi: 10.1001/jamapediatrics.2024.3935.

Medicaid Accountable Care Organizations and Disparities in Pediatric Asthma Care

Affiliations
Comment

Medicaid Accountable Care Organizations and Disparities in Pediatric Asthma Care

Kimberley H Geissler et al. JAMA Pediatr. .

Abstract

Importance: Nearly 6 million children in the US have asthma, and over one-third of US children are insured by Medicaid. Although 23 state Medicaid programs have experimented with accountable care organizations (ACOs), little is known about ACOs' effects on longstanding insurance-based disparities in pediatric asthma care and outcomes.

Objective: To determine associations between Massachusetts Medicaid ACO implementation in March 2018 and changes in care quality and use for children with asthma.

Design, setting, and participants: Using data from the Massachusetts All Payer Claims Database from January 1, 2014, to December 31, 2020, we determined child-years with asthma and used difference-in-differences (DiD) estimates to compare asthma quality of care and emergency department (ED) or hospital use for child-years with Medicaid vs private insurance for 3 year periods before and after ACO implementation for children aged 2 to 17 years. Regression models accounted for demographic and community characteristics and health status. Data analysis was conducted between January 2022 and June 2024.

Exposure: Massachusetts Medicaid ACO implementation.

Main outcomes and measures: Primary outcomes were binary measures in a calendar year of (1) any routine outpatient asthma visit, (2) asthma medication ratio (AMR) greater than 0.5, and (3) any ED or hospital use with asthma. To determine the statistical significance of differences in descriptive statistics between groups, χ2 and t tests were used.

Results: Among 376 509 child-year observations, 268 338 (71.27%) were insured by Medicaid and 73 633 (19.56%) had persistent asthma. There was no significant change in rates of routine asthma visits for Medicaid-insured child-years vs privately insured child-years post-ACO implementation (DiD, -0.4 percentage points [pp]; 95% CI, -1.4 to 0.6 pp). There was an increase in the proportion with AMR greater than 0.5 for Medicaid-insured child-years vs privately insured in the postimplementation period (DiD, 3.7 pp; 95% CI, 2.0-5.4 pp), with absolute declines in both groups postimplementation. There was an increase in any ED or hospital use for Medicaid-insured child-years vs privately insured postimplementation (DiD, 2.1 pp; 95% CI, 1.2-3.0 pp), an 8% increase from the preperiod Medicaid use rate.

Conclusions and relevance: Introduction of Massachusetts Medicaid ACOs was associated with persistent insurance-based disparities in routine asthma visit rates; a narrowing in disparities in appropriate AMR rates due to reductions in appropriate rates among those with private insurance; and worsening disparities in any ED or hospital use for Medicaid-insured children with asthma compared to children with private insurance. Continued study of changes in pediatric asthma care delivery is warranted in relation to major Medicaid financing and delivery system reforms.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Krishnan reported grants from the National Institutes of Hhealth during the conduct of the study; a contract for a chronic obstructive pulmonary disease (COPD) clinical trial from the US Patient Centered Outcomes Research Institute; grants from the American Lung Association and the COPD Foundation outside the submitted work; consultant fees paid to his institution from AstraZeneca for monoclonal antibodies for asthma and from CereVu Medical for a medical device for dyspnea; consultant fees from BData and the American Board of Internal Medicine; personal fees from Verona Pharma for serving on an advisory board and from DynaMed outside the submitted work; and serving on the board of directors for the Global Initiative for Asthma and the Respiratory Health Association. No other disclosures were reported.

Comment on

References

    1. Pate CA, Zahran HS, Qin X, Johnson C, Hummelman E, Malilay J. Asthma surveillance - United States, 2006-2018. MMWR Surveillance Summaries. 2021;70(5):1–32. doi: 10.15585/mmwr.ss7005a1 - DOI - PMC - PubMed
    1. National Asthma Control Program. Uncontrolled asthma among children with current asthma, 2018–2020. US Centers for Disease Control and Prevention. Accessed December 5, 2022. https://archive.cdc.gov/www_cdc_gov/asthma/asthma_stats/uncontrolled-ast...
    1. Holsey CN, Collins P, Zahran H. Disparities in asthma care, management, and education among children with asthma. Clin Pulmonary Med. 2013;20(4):172–177. doi: 10.1097/CPM.0b013e3182991146 - DOI - PMC - PubMed
    1. Canino G, Koinis-Mitchell D, Ortega AN, McQuaid EL, Fritz GK, Alegría M. Asthma disparities in the prevalence, morbidity, and treatment of Latino children. Soc Sci Med. 2006;63(11):2926–2937. doi: 10.1016/j.socscimed.2006.07.017 - DOI - PubMed
    1. Akinbami LJ, Sullivan SD, Campbell JD, et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol. 2012;129(3)(suppl):S49–S64. doi: 10.1016/j.jaci.2011.12.984 - DOI - PMC - PubMed